Victoria Johnson

There were also no significant differences in clinical parameters at baseline for patients initiating first-line or not first-line therapy.

All patients had persistent tumor responses, with 2 complete responses and 1 case of stable disease.

Types of occupation did not significantly affect response to treatment.

Patients also experienced a substantial decrease in systolic blood pressure and diastolic blood pressure.

Notably, people with fewer vaccine doses were more likely to experience post-acute sequelae of COVID-19.

There were no differences in risk between patients with RA or PsA using or not using methotrexate.

Hs-cTnT was found to be associated with a higher risk of MACE and all-cause mortality in a 10-year cohort study.

Substitutors also reported fewer adverse events and greater social acceptance with MC.

In general, current drinkers had a higher risk than never drinkers among men but not women.

There may be a relationship between the inflammatory processes of fibromyalgia and celiac disease.

Wells discussed the PrismRA blood test, which may benefit planning treatment regimens for patients with rheumatic disease.

Although only 9 patients with FM and nasal septum deviation were included in the study, none met the criteria for fibromyalgia after surgery.

Wells discussed the importance and recommended frequency for several factors, including lipid panels, chest X-rays, pregnancy tests, and flu vaccines.

Patients with high RF concentration treated with CZP were more likely to achieve DAS28-CRP low disease activity at week 104 than those treated with adalimumab.

Investigators analyzed levels of CXCL10, MMP3, S100A8, ACP5, and CCL2 in patients treated with biologics and methotrexate.

Mease went over research initiatives including the ARGO, AXIS, and STAR studies.

The MTX + HCQ group had a higher, but not statistically significant, incidence rate of TEAEs than the monotherapy group.

The rheumatology month in review emphasize's bimekizumab's efficacy in treating PsA and new risk factors and mitigators for developing gout or hyperuricemia.

Investigators noted that a formal independent validation cohort needs to be developed in order to realize the full potential of the human model.

Investigators identified 6 themes during semistructed interviews that contributed to and described the experience of people with gout.

Researchers identified 2 genes associated with increased risk and 3 associated with decreased risk.

Mease discussed data supporting FDA approval for the indications in Fall 2024.

Those with limited health literacy had higher disease activity and more SLE damage.

Dialysis efficiency was similar between the ULT group and the no ULT group.

Lengths of stay, total cost, and hospital mortality rates were similar between patients with and without rheumatoid arthritis.

Investigators found that 107 metabolites were associated with the incidence of hospitalized gout.

Investigators also found that bDMARDs were used more often by patients with early-onset rheumatoid arthritis than by patients with late-onset.

Molybdenum’s antioxidative properties may help reduce systemic inflammation, ROS, and uric acid levels.

Productivity improved in patients with IA after starting treatment.